[8-K] Ocuphire Pharma, Inc. Common Stock Reports Material Event
Opus Genetics, Inc. reported that on August 13, 2025 it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and the company also furnished a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.1. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act or incorporated by reference except by specific reference in a later filing. The report shows Opus Genetics is a Delaware corporation and lists its common stock trading under the ticker IRD on Nasdaq. The document is signed by Dr. George Magrath, Chief Executive Officer.
Opus Genetics, Inc. ha comunicato che il 13 agosto 2025 ha diffuso un comunicato stampa con i risultati finanziari del secondo trimestre chiuso il 30 giugno 2025. Il comunicato è fornito come Exhibit 99.1 a questo Current Report e la società ha inoltre fornito un Cover Page Interactive Data File (Inline XBRL) come Exhibit 104.1. Il deposito specifica che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono furnished, not filed, e pertanto non sono soggette alla Section 18 dell'Exchange Act né incorporate per riferimento, salvo un esplicito richiamo in un successivo deposito. Il rapporto indica che Opus Genetics è una società del Delaware e che le sue azioni ordinarie sono negoziate al Nasdaq con il ticker IRD. Il documento è firmato dal Dott. George Magrath, Chief Executive Officer.
Opus Genetics, Inc. informó que el 13 de agosto de 2025 emitió un comunicado de prensa con los resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 a este Current Report y la compañía también adjuntó un Cover Page Interactive Data File (Inline XBRL) como Exhibit 104.1. El filing indica que la información en el Item 2.02 y en el Exhibit 99.1 está furnished, not filed, por lo que no está sujeta a la Section 18 del Exchange Act ni se incorpora por referencia salvo que se haga una referencia específica en un filing posterior. El informe muestra que Opus Genetics es una sociedad de Delaware y que sus acciones comunes cotizan en Nasdaq bajo el ticker IRD. El documento está firmado por el Dr. George Magrath, Chief Executive Officer.
Opus Genetics, Inc.는 2025년 8월 13일자로 2025년 6월 30일에 종료된 2분기 재무실적을 발표하는 보도자료를 발행했다고 보고했습니다. 해당 보도자료는 이 Current Report의 Exhibit 99.1로 제공되었고, 회사는 또한 Cover Page Interactive Data File (Inline XBRL)을 Exhibit 104.1로 제출했습니다. 제출서류에는 Item 2.02와 Exhibit 99.1의 정보가 furnished, not filed로 제공되어 Section 18 of the Exchange Act의 적용을 받지 않으며, 추후 제출서류에서 명시적으로 참조되는 경우를 제외하고는 참조로서 통합되지 않는다고 명시되어 있습니다. 보고서에는 Opus Genetics가 델라웨어 법인임이 기재되어 있으며, 보통주는 Nasdaq에서 IRD라는 티커로 거래된다고 나와 있습니다. 문서에는 Dr. George Magrath, Chief Executive Officer의 서명이 있습니다.
Opus Genetics, Inc. a annoncé que le 13 août 2025 elle avait publié un communiqué de presse présentant ses résultats financiers du deuxième trimestre clos le 30 juin 2025. Le communiqué est fourni en tant que Exhibit 99.1 au présent Current Report et la société a également fourni un Cover Page Interactive Data File (Inline XBRL) en tant qu'Exhibit 104.1. Le dépôt précise que les informations figurant à l'Item 2.02 et dans l'Exhibit 99.1 sont furnished, not filed, et ne sont donc pas soumises à la Section 18 de l'Exchange Act ni incorporées par renvoi, sauf mention expresse dans un dépôt ultérieur. Le rapport indique qu'Opus Genetics est une société du Delaware et que ses actions ordinaires sont cotées au Nasdaq sous le symbole IRD. Le document est signé par Dr. George Magrath, Chief Executive Officer.
Opus Genetics, Inc. teilte mit, dass es am 13. August 2025 eine Pressemitteilung mit den Finanzergebnissen für das zweite Quartal zum 30. Juni 2025 veröffentlicht hat. Die Pressemitteilung ist diesem Current Report als Exhibit 99.1 beigefügt und das Unternehmen hat außerdem eine Cover Page Interactive Data File (Inline XBRL) als Exhibit 104.1 bereitgestellt. Die Einreichung stellt klar, dass die Angaben in Item 2.02 und Exhibit 99.1 als furnished, not filed gelten und daher nicht Section 18 des Exchange Act unterliegen und nicht durch Verweis übernommen werden, außer durch ausdrückliche Bezugnahme in einer späteren Einreichung. Der Bericht weist aus, dass Opus Genetics eine Gesellschaft nach Delaware-Recht ist und dass seine Stammaktien an der Nasdaq unter dem Ticker IRD gehandelt werden. Das Dokument ist unterzeichnet von Dr. George Magrath, Chief Executive Officer.
- None.
- The 8-K does not include the actual financial figures for the quarter; readers must consult Exhibit 99.1 for substantive results.
- The filing explicitly states the press release is furnished, not filed, which limits Section 18 liability and may reduce direct legal incorporation of the release into future filings.
Insights
TL;DR: Routine disclosure of quarterly results; no financial figures included in this filing itself.
The 8-K notifies investors that the company issued a press release for Q2 2025 results and attaches that release as Exhibit 99.1. Crucially, the 8-K itself does not present any revenue, earnings, cash flow, or balance sheet numbers; it only furnishes the press release and Inline XBRL cover page. Because the release is "furnished, not filed," the company distances these disclosures from Section 18 liability. Investors must review Exhibit 99.1 for substantive financial metrics; absent those figures, this filing is a procedural disclosure rather than a standalone earnings report.
TL;DR: Proper procedural filing; signature and exhibit indexing are in order but substantive detail is delegated to the press release exhibit.
The form identifies the press release and Inline XBRL cover page as exhibits and includes an authorized signature from the CEO, meeting Form 8-K procedural requirements. The explicit statement that the information is "furnished and shall not be deemed 'filed'" is standard governance language to limit incorporation by reference. This 8-K does not disclose management changes, material transactions, or detailed financial disclosures within the body of the filing; those items, if present, would need to appear in the press release or subsequent filings.
Opus Genetics, Inc. ha comunicato che il 13 agosto 2025 ha diffuso un comunicato stampa con i risultati finanziari del secondo trimestre chiuso il 30 giugno 2025. Il comunicato è fornito come Exhibit 99.1 a questo Current Report e la società ha inoltre fornito un Cover Page Interactive Data File (Inline XBRL) come Exhibit 104.1. Il deposito specifica che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono furnished, not filed, e pertanto non sono soggette alla Section 18 dell'Exchange Act né incorporate per riferimento, salvo un esplicito richiamo in un successivo deposito. Il rapporto indica che Opus Genetics è una società del Delaware e che le sue azioni ordinarie sono negoziate al Nasdaq con il ticker IRD. Il documento è firmato dal Dott. George Magrath, Chief Executive Officer.
Opus Genetics, Inc. informó que el 13 de agosto de 2025 emitió un comunicado de prensa con los resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 a este Current Report y la compañía también adjuntó un Cover Page Interactive Data File (Inline XBRL) como Exhibit 104.1. El filing indica que la información en el Item 2.02 y en el Exhibit 99.1 está furnished, not filed, por lo que no está sujeta a la Section 18 del Exchange Act ni se incorpora por referencia salvo que se haga una referencia específica en un filing posterior. El informe muestra que Opus Genetics es una sociedad de Delaware y que sus acciones comunes cotizan en Nasdaq bajo el ticker IRD. El documento está firmado por el Dr. George Magrath, Chief Executive Officer.
Opus Genetics, Inc.는 2025년 8월 13일자로 2025년 6월 30일에 종료된 2분기 재무실적을 발표하는 보도자료를 발행했다고 보고했습니다. 해당 보도자료는 이 Current Report의 Exhibit 99.1로 제공되었고, 회사는 또한 Cover Page Interactive Data File (Inline XBRL)을 Exhibit 104.1로 제출했습니다. 제출서류에는 Item 2.02와 Exhibit 99.1의 정보가 furnished, not filed로 제공되어 Section 18 of the Exchange Act의 적용을 받지 않으며, 추후 제출서류에서 명시적으로 참조되는 경우를 제외하고는 참조로서 통합되지 않는다고 명시되어 있습니다. 보고서에는 Opus Genetics가 델라웨어 법인임이 기재되어 있으며, 보통주는 Nasdaq에서 IRD라는 티커로 거래된다고 나와 있습니다. 문서에는 Dr. George Magrath, Chief Executive Officer의 서명이 있습니다.
Opus Genetics, Inc. a annoncé que le 13 août 2025 elle avait publié un communiqué de presse présentant ses résultats financiers du deuxième trimestre clos le 30 juin 2025. Le communiqué est fourni en tant que Exhibit 99.1 au présent Current Report et la société a également fourni un Cover Page Interactive Data File (Inline XBRL) en tant qu'Exhibit 104.1. Le dépôt précise que les informations figurant à l'Item 2.02 et dans l'Exhibit 99.1 sont furnished, not filed, et ne sont donc pas soumises à la Section 18 de l'Exchange Act ni incorporées par renvoi, sauf mention expresse dans un dépôt ultérieur. Le rapport indique qu'Opus Genetics est une société du Delaware et que ses actions ordinaires sont cotées au Nasdaq sous le symbole IRD. Le document est signé par Dr. George Magrath, Chief Executive Officer.
Opus Genetics, Inc. teilte mit, dass es am 13. August 2025 eine Pressemitteilung mit den Finanzergebnissen für das zweite Quartal zum 30. Juni 2025 veröffentlicht hat. Die Pressemitteilung ist diesem Current Report als Exhibit 99.1 beigefügt und das Unternehmen hat außerdem eine Cover Page Interactive Data File (Inline XBRL) als Exhibit 104.1 bereitgestellt. Die Einreichung stellt klar, dass die Angaben in Item 2.02 und Exhibit 99.1 als furnished, not filed gelten und daher nicht Section 18 des Exchange Act unterliegen und nicht durch Verweis übernommen werden, außer durch ausdrückliche Bezugnahme in einer späteren Einreichung. Der Bericht weist aus, dass Opus Genetics eine Gesellschaft nach Delaware-Recht ist und dass seine Stammaktien an der Nasdaq unter dem Ticker IRD gehandelt werden. Das Dokument ist unterzeichnet von Dr. George Magrath, Chief Executive Officer.
FAQ
What did Opus Genetics (IRD) disclose in this 8-K?
Are the Q2 2025 financial figures included in the 8-K?
Is the press release in this filing considered "filed" or "furnished"?
Which exhibits are attached to this Current Report?
Who signed the 8-K for Opus Genetics?
